Chemomab Therapeutics (CMMB) Profit After Tax (QoQ) (2018 - 2025)
Chemomab Therapeutics (CMMB) Profit After Tax (QoQ) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Chemomab Therapeutics | 729.63 Mn | 719.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.52% |
| Sep 30, 2025 | -15.31% |
| Jun 30, 2025 | -38.10% |
| Mar 31, 2025 | 12.15% |
| Dec 31, 2024 | -14.93% |
| Sep 30, 2024 | -4.08% |
| Jun 30, 2024 | -6.13% |
| Mar 31, 2024 | 108.59% |
| Dec 31, 2023 | -1,203.28% |
| Sep 30, 2023 | -48.80% |
| Jun 30, 2023 | -8.95% |
| Mar 31, 2023 | 118.62% |
| Dec 31, 2022 | -681.93% |
| Sep 30, 2022 | 30.53% |
| Jun 30, 2022 | 221.28% |
| Mar 31, 2022 | -1.35% |
| Dec 31, 2021 | -69.68% |
| Sep 30, 2021 | -7.15% |
| Jun 30, 2021 | -62.56% |
| Mar 31, 2021 | 12.66% |